Αρχική World News Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described

Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described

Data from genomic and histologic analyses in the KRYSTAL-1 study show that a diversity of on-target and off-target mechanisms can confer resistance to KRASG12C inhibition and support the need for development of additional KRAS inhibitors with alternative modes of binding and different allele specificities. According to Dr. Andrew Aguirre, Dr. Mark Awad of the Department of Medical Oncology, Dana–Farber Cancer Institute in Boston, MA, US and colleagues development of effective combination therapy regimens will be required to fully combat resistance mechanisms that emerge during treatment with adagrasib or sotorasib. They published their findings on 24 June 2021 in The New England Journal of Medicine.

KRAS glycine-to-cysteine amino acid substitutions at codon 12 (KRASG12C) mutations occur in approximately 13% of lung adenocarcinomas and approximately 3% of colorectal adenocarcinomas and less commonly in cancers of the uterus, pancreas, breast, bladder, cervix, and ovaries.

Little is known about the clinical mechanisms of resistance to KRASG12C inhibition. Despite the clinical benefit observed in patients treated with KRASG12C inhibitors, acquired resistance to single agent therapy occur in most patients. Among patients with KRASG12C-mutant cancers treated with adagrasib in the KRYSTAL-1 study, the investigators performed histologic and genomic analyses that compared pretreatment samples with those obtained after the development of resistance.

They used a deep mutational scanning screen with a library of KRASG12C missense variants to systematically define possible second-site mutations that confer resistance to KRASG12C inhibition.

In total, 38 patients were included in the analysis, 27 with non–small cell lung cancer, 10 with colorectal cancer and 1 with appendiceal cancer. Putative mechanisms of resistance to adagrasib were detected in 17 patients (45% of the cohort), of whom 7 (18% of the cohort) had multiple coincident mechanisms.

Acquired KRAS alterations included G12D/R/V/W, G13D, Q61H, R68S, H95D/Q/R, Y96C, and high-level amplification of the KRASG12C allele.

Acquired bypass mechanisms of resistance included MET amplification; activating mutations in NRAS, BRAF, MAP2K1, and RET; oncogenic fusions involving ALK, RET, BRAF, RAF1, and FGFR3; and loss-of-function mutations in NF1 and PTEN.

In 2 of 9 patients with lung adenocarcinoma for whom paired tissue-biopsy samples were available, histologic transformation to squamous cell carcinoma was observed without identification of any other resistance mechanisms.

By using an in vitro deep mutational scanning screen, the study team systematically defined the landscape of KRAS mutations that confer resistance to KRASG12C inhibitors.

In this study involving patients who initially had a response to adagrasib or who had a long period of stable disease in response to the drug but then had progression, diverse mechanisms of acquired resistance were found in 45%. Unlike resistance to the tyrosine kinase inhibitors, the cancer cells use many mechanisms to overcome KRASG12C inhibition and new therapeutic strategies are required to delay and overcome this drug resistance.

The study was funded by Mirati Therapeutics and grants from multiple non-profit organisations.


Awad MM, Liu S, Rybkin II, et al. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med 2021;384:2382-2393. DOI: 10.1056/NEJMoa2105281



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Foodie Friday: It’s Berry Season!

July is National Berry Month! If berries aren’t part of your daily diet, now is the perfect time to start eating more of these...

No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia

On 23 July 2021, the European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Use (CHMP) has endorsed findings of...

Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home

A woman was 9 months pregnant when she found a pregnant stray cat. Unable to bear the thought of the fellow mom giving birth...

3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout

Karen Warner Schueler is the president of her own executive coaching firm and author of The Sudden Caregiver: A Roadmap for Resilient Caregiving. For...

FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL

July 29, 2021, by NCI Staff FDA's approval of Rylaze is expected to help address a long-running shortage of the drug Erwinia asparaginase for kids...

EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib

On 22 July 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...